Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAF^V600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland

1Department of Oncology, University Hospital of Lausanne; 2Genomic Technologies Facility (GTF), Center for Integrative Genomics, University of Lausanne; 3Vital-IT, Swiss Institute of Bioinformatics, and the 4Ludwig Center for Cancer Research of the University of Lausanne, Lausanne, Switzerland